Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
76 hedge funds and large institutions have $205M invested in Astria Therapeutics in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 16 closing their positions.
69% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 16
17% more funds holding
Funds holding: 65 → 76 (+11)
4.36% more ownership
Funds ownership: 83.64% → 88% (+4.4%)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
1% more call options, than puts
Call options by funds: $188K | Put options by funds: $187K
34% less capital invested
Capital invested by funds: $312M → $205M (-$106M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$6.19M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.67M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.7M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.46M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.77M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.35M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.95M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.4M |
ATXS Hedge Fund Activity: Q2 2023 in Review
76 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2023, worth a combined $205M — down 34% from $312M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ATXS positions and 16 closed out — a net gain of 11 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $6.46M sold.
- 76 institutional investors held Astria Therapeutics (ATXS) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $205M of Astria Therapeutics stock for Q2 2023, down 34% quarter-over-quarter.
- 27 funds opened new Astria Therapeutics positions in Q2 2023 and 16 closed out, a net change of +11 holders.
- The largest Astria Therapeutics buyer in Q2 2023 was BlackRock, an estimated $15.7M added.
- The largest Astria Therapeutics seller in Q2 2023 was Balyasny Asset Management, an estimated $6.46M sold.
Based on aggregated 13F filings for Q2 2023.